ESMO: Pfizer's Lorbrena Makes Case To Claim ALK+ Lung Cancer CROWN
But 'Unique Side Effects' A Concern
Executive Summary
Lorbrena is approved as a second-line treatment for ALK-positive NSCLC but Pfizer believes data from the first-line Phase III CROWN study makes the drug a serious competitor to standard of care Alecensa in the first-line setting.
You may also be interested in...
Pfizer Embraces Biotech-Like Speed To Advance BCMA Bispecific
Chris Boshoff, Pfizer Oncology chief development officer, said lessons from the rapid pace of the company’s COVID-19 vaccine program are being applied to elranatamab and other cancer therapies.
Keeping Track: Chiesi Breathes Easier With Bronchitol Approval; Submissions Aplenty From GSK, Pfizer, AZ, AbbVie
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Quick Listen: Scrip’s Five Must-Know Things
Join us for an audio roundup of major events in the global biopharma industry over the past week, as reported by Scrip.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports